Category Archives: Epigenetics

A detailed synopsis of the epigenetics market has been presented in this research report. The synopsis has been charted out keeping in mind certain vital parameters such as global trends, industry insights, growth drivers, industry ecosystem analysis, and market segmentation. Details about the various companies constituting he competitive landscape of market as well as the regional bifurcation of this industry from a global standpoint is outlined in the study, in addition to the impact of the regulatory frame of reference worldwide.

Get sample copy of this research report @ https://www.gminsights.com/request-sample/detail/4244

What are some of the pivotal parameters that the epigenetics industry report encompasses pertaining to the Product landscape?

Market segmentation as per the Product landscape: Enzymes, Instruments and Consumables, Kits, Reagents, Bioinformatic tools, etc.

Market Share:

Revenue:

What are some of the pivotal parameters that the epigenetics industry report encompasses pertaining to the Application landscape?

Market segmentation as per the Application landscape: Oncology, Immunology, Cardiovascular diseases, Developmental biology, etc.

Market Share:

Revenue:

What are some of the pivotal parameters that the epigenetics market report encompasses pertaining to the Technology landscape?

Market segmentation as per the Technology landscape: Histone Modification, DNA Methylation, Others, etc.

Market Share:

Revenue:

Request for customization @ https://www.gminsights.com/roc/4244

The epigenetics market research document is an extensive collection of pivotal insights pertaining to the industry. In a nutshell, the epigenetics market study aims to educate potential investors about the market scenario and future prospects. The report also endorses details about the industry pitfalls and challenges as well as the industry impact forces.

View original post here:
Epigenetics Market Is Predicted to Witness A Massive Growth Up To 2026 - Fractovia News

The links between methionine consumption, epigenetic patterns, and T-cell exhaustion were recently uncovered by scientists based at the University of Michigan. According to these scientists, who were led by Weiping Zou, M.D., Ph.D., targeting cancer methionine signaling could provide an immunotherapeutic approach.

Tumor cells compete with T cells for methionine, an amino acid that T cells need to maintain their histone patterns. Unfortunately, T cells consistently lose. When their histone patterns suffer, the T cells become dysfunctional, lose their fighting spirit, and let tumors grow. Could this discouraging chain of events be interrupted? Perhaps, if the right immunotherapeutic approach can be developed.

Details of the scientists work appeared September 2 in the journalNature, in an article titled, Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. The article describes how tumor cells greedily consume methionine, denying it to CD8+T cells, which endure lower intracellular levels not only of methionine, but of the methyl donorS-adenosylmethionine (SAM).

The implications of SAM deficiency are dire. It results in reduced dimethylation at lysine 79 of histone H3 (H3K79me2) and, consequently, impaired expression of STAT5, a protein that signals T cells to sustain antitumor immunity.

As the scientists teased out these details, they considered a key question: How is it that tumor cells outcompete T cells for methionine? The answer to this question, the scientists knew, could point to new immunotherapeutic approaches.

The scientists determined that tumor cells outcompete T cells for methionine via SLC43A2, a major methionine transporter. Given that SLC43A2 is highly expressed on multiple human and mouse tumor cells with different genetic backgrounds, abnormal tumor SLC43A2 and its related methionine metabolism are unlikely to be driven by shared key oncogenes, the authors of the Naturearticle noted. Inhibition of tumor SLC43A2 can normalize methionine metabolism in effector T cells and rescue their function, and it can also improve spontaneous and checkpoint blockade-induced antitumor immunity in preclinical models.

Previous research had considered a systemic approach to starve tumor cells of methionine, with the idea that the tumor cells are addicted to it. But the current study shows why that approach may be a double-edged sword.

You have competition between tumor cells and T cells for methionine, said Zou. The T cells also need it. If you starve the tumor cells of methionine, the T cells dont get it either. You want to selectively delete the methionine for the tumor cells and not for the T cells.

In fact, the study found that supplementing methionine actually restored T-cell function. High enough levels of methionine meant there was enough for both tumor cells and T cells.

Genetic and biochemical inhibition of tumor SLC43A2 restored H3K79me2 in T cells, thereby boosting spontaneous and checkpoint-induced tumor immunity, the scientists reported. Moreover, methionine supplementation improved the expression of H3K79me2 and STAT5 in T cells, and this was accompanied by increased T cell immunity in tumor-bearing mice and patients with colon cancer. Clinically, tumor SLC43A2 correlated negatively with T cell histone methylation and functional gene signatures.

Tumor cells have more of the transporters that deliver methionine. Impairing those transporters, the researchers found, resulted in healthier T cells because the T cells were able to compete for methionine.

There are still a lot of mechanistic details we have not worked out, particularly the detailed metabolic pathways of methionine metabolism, Zou noted. We also need to understand how metabolism pathways may be different from tumor cells and T cells. We hope to find a target that is relatively specific to tumor cells so that we do not harm the T cells but impact the tumor.

In the meantime, Zou is working with drug discovery experts to identify a small molecule inhibitor that targets methionine in tumor cells.

Read more from the original source:
Researchers Link Epigenetics, T Cell Exhaustion, and Methionine to Tumor Growth - Clinical OMICs News

Yes, even your metabolism has a memory and it can hold a grudge for years. In people with diabetes, periods of high blood sugar can negatively impact their health years later, even if they get their blood sugar under control. While this metabolic memory phenomenon has been known for years, why it happens is poorly understood.

Rama Natarajan, Ph.D., Professor and Chair of the Department of Diabetes Complications & Metabolism at City of Hope, turned to our epigenome for the answer.

Weve shown the first link between DNA methylation in blood and stems cells, blood sugar history, and future development of complications, said Natarajan. This highlights the importance of good glycemic control to prevent long-term complications.

The history of metabolic memory

We now know high blood sugar can lead to a variety of complications, including eye disease, kidney disease, nerve problems, heart disease, and stroke. But the relationship between strict blood sugar control and complication risk wasnt well understood before the 1980s.

Back in 1983, the Diabetes Control and Complications Trial (DCCT) began tracking complications in 1,441 participants with type 1 diabetes. Researchers compared the occurrence of long-term complications between participants who tightly regulated their blood glucose levels to those who followed less strict standard regulation.

After 10 years, the difference was striking the risk of diabetic complications was reduced in participants who tightly regulated their blood sugar but not in those following standard regulation. In other words, a person with higher blood sugar had a higher risk of complications.

To continue following the DCCT patients, the Epidemiology of Diabetes Interventions and Complications (EDIC) follow-up trial began at the end of DCCT in 1993 and is ongoing. At the end of DCCT, all participants were encouraged to adopt strict blood sugar regulation; many in the standard regulation group did.

Despite blood sugar regulation being very similar in all the patients (as measured by hemoglobin A1c, called HbA1c), differences persisted between the two original intervention groups. The phenomenon of long-term effects from high or variable blood sugar control is called metabolic memory (or the legacy effect in type 2 diabetes).

Complications resulted from total high blood sugar exposure it didnt matter whether the person was exposed to slightly elevated levels over a long time or high levels over a short time.

So, what caused the sweet sugar molecule to become so destructive?

Sugary destruction

Extra sugar in your blood can interact with your cells, DNA, and proteins, adding itself onto things it shouldnt be on through a process called glycation. In fact, HbA1c can be thought of as sugar-coated red blood cells.

The sugar-coated molecules cant function as well, if at all, and the damage begins a self-perpetuating cycle. Not only do these damaged molecules stop working, they can also accumulate in the skin, eyes, and other organs, causing damage. Build-up of sugar-coated molecules can trigger the creation of harmful free radicals, causing oxidative stress and feeding a destructive cycle.

Although sugar can directly modify molecules, it can also trigger other epigenetic modifications. These modifications can control how genes are expressed, changing protein levels in cells.

There hasnt been a strong genetic association with diabetic complications very few genetic mutations have been strongly linked to complications, Natarajan explained. But we knew the epigenome is what makes identical twins different and can have implications into why one gets diabetes or cancer and the other doesnt. So, we turned our focus to epigenetics.

Epigenetics and diabetes

Natarajan sought to explain the long-term sugary destruction wrought by high blood sugar by searching the epigenome. Her lab specifically looks for one type of modification called DNA methylation, where a tiny molecule called a methyl group is added onto DNA.

Epigenetics is the coating on top of genetics that can be altered by environmental influences, Natarajan said. We started focusing on the role of epigenetics in developing diabetes and its complications because we know that lifestyles, improper diet, lack of exercise, and even viruses can affect epigenetics.

Natarajans lab began collaborating with the DCCT trial group, analyzing data collected through the trial for epigenetic clues to explain the metabolic memory of complications. They found more modifications associated with active genes on proteins called histones that are wrapped by DNA in participants with regular blood sugar control compared to the strict controllers. Even more interesting was that many epigenetic DNA methylation variations between the two groups persisted through at least 17 years of follow-up in the EDIC study.

These changes were in important genes related to complications, showing something about persistent epigenetic programming in peripheral blood cells, commented Natarajan. Previous high blood sugar episodes could be a key factor in why these genes were continually misbehaving.

Now, Natarajans lab illuminated even more links between epigenetic changes, blood sugar history, and metabolic memory in their recent Nature Metabolism paper. Persistent epigenetic modifications of a few key genes were detected in participants with previously less regulated blood sugar who developed either retinopathy or nephropathy. They showed that DNA methylation is a key link between a patients HbA1c history, metabolic memory, and development of future complications.

Many HbA1c-associated modifications were in stem cells and the blood cells they create. Even though blood cells are turned over relatively quickly, stem cells stick around for a long-time, so changes in stem cells can have long-term consequences.

The important thing we found was the connection to stem cells, explained Natarajan. Were asking how these changes alter inflammatory gene expression and how we can interrupt those pathways.

Sugar-modified genes arent so sweet

Natarajans lab sorted through all the modified genes to find the most common modifications in participants with less strict blood sugar control. The most commonly modified gene coded for thioredoxin-interacting protein (TxNIP).

TxNIP is not a new protein, but the discovery that its DNA methylation is altered by different glycemic control is new, Natarajan added.

Thioredoxin-interacting protein is known to be highly regulated in certain pancreas cells, called beta cells, that release insulin. The plot thickened when high blood sugar was found to increase TxNIP protein production. Even more interesting, high TxNIP protein levels make beta-cells dysfunctional, ultimately leading to their untimely death. So, high blood sugar triggers more TxNIP to be produced, possibly through epigenetic modifications of the TxNIP gene, which ultimately leads to the death of insulin-producing beta cells.

Showing that the TxNIP gene can be epigenetically modified for years and years suggests that it could be one of the culprits causing long-term problems in diabetes, Natarajan said.

The proteins that TxNIP interacts with, called thioredoxins, protect against oxidative stress. TxNIP can bind to and inactivate thioredoxin to increase oxidative stress by increasing reactive oxygen species (ROS). In mouse cells in a dish, high glucose exposure triggered increased ROS levels mediated by TxNIP, leading to oxidative stress. Oxidative stress can trigger cell and organ damage, so this could be one mechanism explaining diabetes-induced damage.

Her lab also found epigenetic changes in other genes related to inflammation and inflammation-related processes.

Next steps and clinical implications

Natarajans lab is continuing to study the link between blood sugar history, epigenetics, and other complications of diabetes. They are also expanding their scope, searching the entire genome for more epigenetic modifications linked with past blood sugar maintenance.

This study also lays the groundwork for further studies with meaningful clinical implications, including developing epigenetic biomarkers for diabetic complications. In the future, Natarajan says a simple blood test looking at key epigenetic modifications, along with HbA1c history, could be used to predict future risk of retinopathy, nephropathy, and neuropathy. This would allow the doctor to figure out who should have early and more aggressive treatment to mitigate complication risk.

While these studies were done in type 1 diabetes patients, other studies in type 2 diabetes patients have shown similar epigenetic modifications after history of higher blood sugar levels.

Turning knowledge into potential drugs

What about doing something about the epigenetic modifications can we remove them? As a matter of fact, yes!

There is an interesting new type of experimental drug on the horizon called epigenetic editing. The hot new technology CRISPR isnt just for cutting out chunks of DNA or controlling genes it can also be used to insert or remove epigenetic modifications. While this technology is still experimental and in early preclinical animal studies, the potential is very exciting.

A CRISPR/enzyme pair can be used the CRISPR genetic material can hunt down the genetic spot you want to change; and the attached enzyme can snip or add certain molecules to the DNA, effectively removing or creating an epigenetic modification, thereby activating or silencing the targeted gene.

Enzymes such as methyltransferase or demethylase can add or remove methyl groups from genes. Because they just change what is on the gene or histone wrapped around it (not the genetic sequence itself), the gene itself isnt tampered with, meaning there could be less genetic complications associated with CRISPR epigenetic editing.

This is a futuristic thing, Natarajan concluded. The combination of genetics and epigenetics is going to be the future of personalized medicine.

Read the original:
Can High Blood Sugar Haunt People with Diabetes Even After it is Under Control? - BioSpace

Fort Collins, Colorado The Epigenetics Market research report offers insightful information on the Epigenetics market for the base year 2019 and is forecast between 2020 and 2027. Market value, market share, market size, and sales have been estimated based on product types, application prospects, and regional industry segmentation. Important industry segments were analyzed for the global and regional markets.

The effects of the COVID-19 pandemic have been observed across all sectors of all industries. The economic landscape has changed dynamically due to the crisis, and a change in requirements and trends has also been observed. The report studies the impact of COVID-19 on the market and analyzes key changes in trends and growth patterns. It also includes an estimate of the current and future impact of COVID-19 on overall industry growth.

Epigenetics market garnered a revenue of USD 7.4 billion in the year 2019 globally and has been foreseen to yield USD 30.1 billion by the year 2027 at a compound annual growth (CAGR) of 18.9% over the forecast period.

Get a sample of the report @ https://reportsglobe.com/download-sample/?rid=81572

The report has a complete analysis of the Epigenetics Market on a global as well as regional level. The forecast has been presented in terms of value and price for the 8 year period from 2020 to 2027. The report provides an in-depth study of market drivers and restraints on a global level, and provides an impact analysis of these market drivers and restraints on the relationship of supply and demand for the Epigenetics Market throughout the forecast period.

The report provides an in-depth analysis of the major market players along with their business overview, expansion plans, and strategies. The main actors examined in the report are:

F. Hoffmann-La Roche Ltd

The Epigenetics Market Report offers a deeper understanding and a comprehensive overview of the Epigenetics division. Porters Five Forces Analysis and SWOT Analysis have been addressed in the report to provide insightful data on the competitive landscape. The study also covers the market analysis and provides an in-depth analysis of the application segment based on the market size, growth rate and trends.

Request a discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=81572

The research report is an investigative study that provides a conclusive overview of the Epigenetics business division through in-depth market segmentation into key applications, types, and regions. These segments are analyzed based on current, emerging and future trends. Regional segmentation provides current and demand estimates for the Epigenetics industry in key regions in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Epigenetics Market Segmentation:

Epigenetics Market, By Technology (2016-2027)

Epigenetics Market, By Application (2016-2027)

Epigenetics Market, By Product (2016-2027)

Request customization of the report @https://reportsglobe.com/need-customization/?rid=81572

Overview of the table of contents of the report:

To learn more about the report, visit @ https://reportsglobe.com/product/epigenetics-market/

Thank you for reading our report. To learn more about report details or for customization information, please contact us. Our team will ensure that the report is customized according to your requirements.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

See the rest here:
Epigenetics Market is Thriving Worldwide 2020-2027 | Top Companies Qiagen, Novartis AG, Active Motif, Merck Sharp & Dohme Corp, Thermo Fisher...

Epigenetics Market 2020: Inclusive Insight

Global Epigenetics Market 2020 provides an in-depth analysis of the current and upcoming market and helps the user to understand theCoronavirus (COVID-19) Impact analysis on marketin terms of its Definition, Segmentation, Market Potential, Influential Trends, and the Challenges that theEpigenetics marketis facing. The Epigenetics industry profile also contains descriptions of the leading topmost manufactures/players like (Illumina, Thermo Fisher Scientific, Merck Millipore, Abcam, Active Motif, Bio-Rad, New England Biolabs, Agilent, Qiagen, Zymo Research, Perkinelmer, Diagenode) which including Capacity, Production, Price, Revenue, Cost, Gross, Gross Margin, Growth Rate, Import, Export, Market Share and Technological Developments. COVID-19 can affect the global economy in three main ways: by directly affectingProduction and Demand, by Creating Supply Chain and Epigenetics Market Disruption, and by its financial impact on firms and financial markets.

>>> To know How COVID-19 Pandemic Will Impact This Market/Industry | Request a Free sample copy of the Epigenetics Market report:

Some of the Major Highlights of TOC covers in Epigenetics Market Report:Chapter 1: Methodology & Scope of Epigenetics Market; Chapter 2: Executive Summary of Epigenetics Market; Chapter 3: Epigenetics Industry Insights; Chapter 4: Epigenetics Market, By Region; Chapter 5: Company Profile; Chapter 6: to show competition and trade situation of Epigenetics Market; Chapter 7: to show the comparison of applications; Chapter 8: to show the comparison of types; Chapter 9: to show an investment of Epigenetics Market; Chapter 10: to forecast Epigenetics market in the next years.

Each segment of the global Epigenetics market is extensively evaluated in the research study. The segmental analysis offered in the report pinpoints key opportunities available in the global Epigenetics market through leading segments. The regional study of the worldwide Epigenetics market included in the report helps readers to gain a sound understanding of the development of different geographical markets in recent years and also going forth. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the market.

Later, the report gives a detailed analysis of the major factors fueling the expansion of Epigenetics Market in the coming years. Some of the major factors driving the growth of the industry are

BuyersSuppliersInvestors End-User Industry

Our exploration specialists acutely ascertain the significant aspects of the global Epigenetics market report. It also provides an in-depth valuation in regards to the future advancements relying on past data and present circumstances of the market situation. In this report, we have investigated the principals, players in the market, geological regions, product type, and market end-client applications. The global Epigenetics report comprises primary and secondary data which is exemplified in the form of pie charts, tables, analytical figures, and reference diagrams. The report is presented in an efficient way that involves basic dialect, a basic outline, agreements, and certain facts as per solace and comprehension.

Key parameters which define the competitive landscape of the Global Epigenetics Market:

Profit Margins Product Sales Company ProfileProduct Pricing ModelsSales Geographies Distribution Channels Industry Evaluation for the Market Contenders

Analysis of Global Epigenetics Market: By Type

DNA Methylation, Histone Modifications, Other Technologies

Analysis of Global Epigenetics Market: By Application

Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Other Applications

>>> To get more information on this Premium Report, Click Here @https://www.syndicatemarketresearch.com/market-analysis/epigenetics-market.html

In terms of region, this research report covers almost all major regions of the world, such as North America, Europe, South America, The Middle East and Africa, and Asia-Pacific. Europe and North America are expected to increase over the next few years. In the Epigenetics market, the Asia Pacific region is expected to grow significantly during the forecast period. The latest technologies and innovations are the most important characteristics of North America and the main reason the United States dominates the world market. The South American market is also expected to grow in the near future.

Table of Contents

Part 1 Market Overview1.1 Market Definition1.2 Market Development1.3 By TypeTable Type of EpigeneticsFigure Global Epigenetics Market Share by Type in 20201.4 By ApplicationTable Application of EpigeneticsFigure Global Epigenetics Market Share by Application in 20201.5 Region OverviewTable Region of EpigeneticsFigure Global Epigenetics Market Share by Region in 2020Part 2 Global Market Status and Future Forecast2.1 Global Market by RegionTable Global Epigenetics Market by Region, 2016-2019 (Million USD)Figure Global Epigenetics Market Share by Region in 2020 (Million USD)Table Price List by Region, 2016-20192.2 Global Market by CompanyTable Global Epigenetics Market by Company, 2016-2019 (Million USD)Figure Global Epigenetics Market Share by Company in 2020 (Million USD)Table Price List by Company, 2016-20192.3 Global Market by TypeTable Global Epigenetics Market by Type, 2016-2019 (Million USD)Figure Global Epigenetics Market Share by Type in 2020 (Million USD)Table Price List by Type, 2016-20192.4 Global Market by ApplicationTable Global Epigenetics Market by Application, 2016-2019 (Million USD)Figure Global Epigenetics Market Share by Application in 2020 (Million USD)Table Price List by Application, 2016-20192.5 Global Market by ForecastFigure Global Epigenetics Market Forecast, 2020-2026 (Million USD)Part 3 Asia-Pacific Market Status and Future Forecast3.1 Asia-Pacific Market by CompanyTable Asia-Pacific Epigenetics Market by Company, 2016-2019 (Million USD)Figure Asia-Pacific Epigenetics Market Share by Company in 2020 (Million USD)Table Price List by Company, 2016-20193.2 Asia-Pacific Market by TypeTable Asia-Pacific Epigenetics Market by Type, 2016-2019 (Million USD)Figure Asia-Pacific Epigenetics Market Share by Type in 2020 (Million USD)Table Price List by Type, 2016-20193.3 Asia-Pacific Market by ApplicationTable Asia-Pacific Epigenetics Market by Application, 2016-2019 (Million USD)Figure Asia-Pacific Epigenetics Market Share by Application in 2020 (Million USD)Table Price List by Application, 2016-20193.4 Asia-Pacific Market by ForecastFigure Asia-Pacific Epigenetics Market Forecast, 2020-2026 (Million USD)

Continued.

>>> Make an Inquiry before buying this report @https://www.syndicatemarketresearch.com/inquiry/epigenetics-market

Note In order to provide a more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.(*If you have any special requirements, please let us know and we will offer you the report as you want.)

Why Syndicate Market Research:

Setting a strong foot in the industry with all planned and tactical approaches is surely not a cakewalk. You need loads of research, analysis, take several factors into consideration, and above all, give your valuable time to the entire process. This is where Syndicate Market Research kicks in as a support system for our clients. Our reports targets high growth emerging markets in the USA, Europe, The Middle East & Africa, and Asia Pacific covering industries like IT and Telecommunications, Machinery & Equipment, Electronics & Semiconductor, Chemicals and Materials, Healthcare & Pharma, Energy & Mining, Manufacturing & Construction, Automotive, Food & Beverage, etc.

Contact Us:

Syndicate Market Research244 Fifth Avenue, Suite N202New York, 10001, United States+1 347 535 0815 |Email ID:[emailprotected]Website:www.syndicatemarketresearch.com

See original here:
Global Epigenetics Market 2020-2026 | COVID-19 Impact & Recovery Analysis Of Key Manufacturers: Illumina, Thermo Fisher Scientific, Merck...

SALT LAKE CITY, Sept. 9, 2020 /PRNewswire/ --Inherent Biosciences, a biotechnology company headquartered in Salt Lake City, UT, today announced a $255,959 award from the National Science Foundation (NSF) to study epigenetic biomarkers to predict patient response to SARS-CoV2 (COVID-19) infection. The Small Business Innovation Research (SBIR) Phase I project aims to develop an on-site, clinical test to screen incoming patients potentially infected with COVID-19 and prioritize hospital resources and personnel based on a predicted infection severity and treatment response.

The variation in symptoms and outcomes for COVID-19 progression makes it challenging for health care workers to triage patients accurately. The development of a DNA methylation-based test to predict the severity of COVID-19 infection has tremendous potential for managing current and future pandemics.

"NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas across all markets and areas of science and engineering," said Andrea Belz, Division Director of the Division of Industrial Innovation and Partnerships at NSF. "With the support of our research funds, any deep technology startup or small business can guide basic science into meaningful solutions that address tremendous needs."

Andy Olson, Co-founder and CEO of Inherent Biosciences, remarked: "We're thrilled to announce this award, which will enable us to expand our discovery and commercialization pipeline into the area of infectious disease - a critical area as witnessed by the COVID-19 pandemic we're living through."

The award provides support for Inherent to generate a comprehensive dataset of white blood cell DNA methylation patterns, health history, and clinical data for patients infected with COVID-19. The company then uses artificial intelligence (AI) and machine learning to identify DNA methylation biomarkers predictive of disease severity and treatment response.

Kristin Brogaard, Ph.D., Co-founder and COO of the company, and Principal Investigator for the project added: "Our focus is translating epigenetic discoveries, specifically DNA methylation biomarkers, from research discoveries into commercial products that benefit consumers, patients and health care providers."

Inherent has already translated one epigenetic discovery into a commercial product. The company's first product called "Path" (PathFertility.com) is for couples trying to conceive. Path is marketed directly to consumers as a general wellness sperm DNA test related to maintaining or encouraging a general state of health, specifically male reproductive health.

About Inherent Biosciences- Inherent Biosciences, Inc. is a molecular diagnostics company at the intersection of epigenetics and AI. Inherent believes that guesswork and trial-and-error medicine lead to severe pain and suffering. Inherent's vision is to revolutionize trial and error medicine and restore hope. The company does this by discovering what is inherent in our biology about the unexplained and translating discoveries into personal insights that inform actions. Learn more at http://www.inherentbio.comor connect on LinkedIn.

Contact: Inherent Biosciences, Inc.

Andy Olson, CEO

Phone: (509) 496-1204

Email: andy@inherentbio.com

Related Images

inherent-biosciences-logo.pngInherent Biosciences LogoCompany logo

Continue reading here:
Inherent Biosciences Wins $256K NSF Grant to Predict COVID-19 Infection Severity and Treatment Response - The Herald Journal

CAMBRIDGE,Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in upcoming virtual investor conferences. Jigar Raythatha, CEO, will present at:

Live audio webcasts of Mr. Raythathas presentations and archives for replay will be available on the Investor Relations section of Constellations website at http://ir.constellationpharma.com/events-and-presentations/events. The audio webcast replays will be available for 30 days following the live presentation.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

Contact

Kia Khaleghpour, Ph.D.Vice President, Investor Relations and CommunicationsConstellation Pharmaceuticals+1 617-844-6859kia.khaleghpour@constellationpharma.com

Ronald Aldridge Investor RelationsConstellation Pharmaceuticals+1 617-714-0539ron.aldridge@constellationpharma.com

Lauren ArnoldMedia RelationsMacDougall Biomedical Communications+1 781-235-3060larnold@macbiocom.com

Follow this link:
Constellation Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences - GlobeNewswire

SAN DIEGO--(BUSINESS WIRE)--San Diego, Calif.-based biotech company Diomics Corp. is aiming to nose out the novel coronavirus ahead of vaccines by using nanosized biopolymer beads to deliver monoclonal antibody protection against COVID-19 via an easy-to-administer nasal spray.

The Dioguard prophylactic spray, which is now undergoing in vitro testing, pairs Diomics proprietary synthetic biopolymer material with human IgG monoclonal antibodies licensed from another San Diego-area company, Active Motif, Inc., a leader in epigenetic research. The goal is to create a durable barrier of antibodies in the nasal cavity to capture, bind to and neutralize the SARS-CoV-2 virus before it can reach and enter the cells that cause infection. Research demonstrating the potent neutralizing ability of Active Motifs 414-1 antibody has appeared in three peer reviewed journals. http://www.dioguard.com/science

Creating a protective shield that blocks the virus at its crucial first point of entry into the body the nasal passages fills a huge void in the race to develop an effective vaccine for COVID-19. A preventative nasal spray that effectively neutralizes SARS-CoV-2 before it can cause infection we believe holds the key to allowing many aspects of life to resume until the day comes when theres an effective vaccine in widespread use, Diomics CEO Anthony Zolezzi said.

Binding the neutralizing antibodies to our propriety nanobeads extends their residency time in the nasal mucosa to up to 24 hours, enabling people to replenish their protection once a day, Zolezzi said.

Since both human monoclonal antibodies and Diomics biocompatible, bioresorbable Diomat polymer have already received FDA approval for other applications, Diomics plans to seek fast track authorization from the agency to accelerate human trials.

About Diomics

Diomics Corporation is a biotechnology company focused on science-based innovation and the development of life-improving products. Our proprietary Diomat technology platform is optimized for the collection and delivery of compounds and proteins and can also be used for drug delivery, long-term monitoring, diagnostics and production of life-saving hormones and other bio-compounds. Based in San Diego, Calif., Diomics has developed numerous products, tools and services for the molecular, diagnostic and forensic industries. For more information visit diomics.com.

About Active Motif

Active Motif, Inc. is dedicated to developing, manufacturing and delivering epigenetics-based research tools to analyze nuclear function. Its customers include life scientists from academic and government institutions, biotechnology and pharmaceutical companies, hospitals, and reference laboratories. Active Motif operates globally through its corporate headquarters in Carlsbad, Calif. and offices in Shanghai, China; Tokyo, Japan; and Waterloo, Belgium. Active Motif applies a multi-disciplinary approach to create new and modify existing technologies to meet the current and future needs of life science researchers.

NOTE TO EDITORS: Additional scientific background, peer-reviewed research and explanatory video are available at http://www.dioguard.com/science.

See the original post here:
Diomics Aims to Nose Out Coronavirus Ahead of Vaccines With Nasal Spray That Delivers Monoclonal Antibody Protection - Business Wire

Active aging allows individuals to continue to stay involved in the workforce and stay engaged with their pension and savings programs.

Photo: Unsplash

Share this article

Some scientists believe that the firstperson to live to 200 years old has already been born. But counting years on the calendar alone puts the focus on quantity, potentially overlooking quality of life, especially if one cannot be active. Modern medicine and technology can save lives; unfortunately, not as much work has gone into preventing illness as into treating it.

The data shows that as life expectancy continues to increase, people are running out of money for essentials, let alone factoring in the costs of maintaining health and seeking care. The pension gap (between actual savings and income needs) in the U.K. in 2015 was already at $8 trillion, estimated to rise at 4% per annum to reach $33 trillion by 2050. If we look at the top eight global economies, these figures are $70 trillion and $400 trillion, respectively, meaning this is not an isolated problem. In the U.K., at an individual level, this equates to running out of money 10.3 years before you die if you are a man and 12.6 years before you die if you are a woman on average. Can you imagine the gap if we live to 200? For many employees, financial stress is already their number one worry, and 85% tell us that they trust their employers to prepare them adequately for retirement.

Working longer whether its because you have to or want to could close these financial gaps if you have the right information and means, but you need to be active to do so. The fastest-growing employment segment in many developed economies is the over-55s, which means a much larger percentage of older workers are now in employment than ever before. In the U.K., over-55s represented more than 50% of employment growth in the decade to 2018, a trend expected to continue in the next 10 years. Its clear, therefore, that we need to find ways to add healthy years to life, not just years.

Its also clear that what we have done in the past has not solved the problem. We need to enable long-term behavior change to ensure that people enjoy better health and stay active. And thats hard.

Many consider genetics to be the cards we are dealt. Our genes are fixed, and therefore, we are left with the bad and the good that come with them. This may well be true to an extent. However, we have something that sits above the genes known as the epigenome a network of chemical compounds surrounding DNA that have a role in determining which genes are active in a particular cell.

The study of these genetic interactions and changes is called epigenetics, which has become a field of urgent and intense research and may offer us a way of looking at how outcomes can be altered. By changing certain environmental factors such as physical activity, diet, stress and chronic pollution levels lets call these lifestyle interventions your genes may start to behave differently, leading to better quality, more energetic and non-sick aging. This active aging allows individuals to continue to participate in social, economic, cultural and civic activities, as well as remain physically active, stay involved in the workforce and stay engaged with their pension and savings programs. Active aging, therefore, could help minimize, or even eliminate, the funding gap. Additionally, healthy older adults are less at risk of severe consequences of COVID-19.

Muhdo Health has found that by testing individuals epigenetics and applying specific lifestyle interventions, we can expect to see an improvement in their quality of life. Workers get the opportunity to keep working for longer, reduce fatigue and, as a result, enjoy a happier retirement with less worry about the need for care in older (chronological) age.

Many types of workers may benefit from this approach. With the help of epigenetic monitoring, adjustments can be made to workflow, stress management and nutrition and the impact could be measured and controlled.

An employer in the building industry found that its older, more experienced workers were essential to the successful delivery of high-end projects. The continued health of this group of employees was so crucial that the employer implemented a Muhdo measure and monitor process to establish what the right working patterns and interventions should be. Once individuals had been tested and knew the steps they could take to improve their quality of life, they could set their own hyper-personalized goals and put change processes in motion.

Behavior change comes at different speeds not everyone can fix a lifetimes worth of bad habits overnight. But knowing how to add healthy years to your life by understanding your epigenetics may certainly help drive behavior change in a positive direction.

In addition to helping employees identify individual action plans, this employer found that it could help further by adjusting work and shift patterns to allow for more flexibility for this group of older, more experienced workers. Creating more flexibility reduced stress levels and improved engagement. This type of flexible work in later life is becoming increasingly prevalent. More than three-quarters (76%) of employees in Mercers 2020 Global Talent Trends Study said that they intended to continue working in some shape or form beyond the official retirement age, and 24% planned to work fewer hours. Up to 57% of employers already offer part-time work pre- and post-retirement as a means to embrace the value of older workers, and 46% are building a pool of retiree talent to tap into. These approaches could become even more useful for everyone by adding healthy active years to the mix.

And if a simple saliva test (repeated at intervals, say, quarterly or annually) could enable a future with less back pain, fewer muscle aches and injuries, less sickness, and even improved mental health as a result of better physical health then workers and employers rejoice!

We believe there are two key learnings to take forward:

Proactive epigenetic testing can enable employees to enjoy more healthy and active years. Epigenetic testing could be the way to unlock much-needed behavior change and the adoption of smarter lifestyle choices.

Flexible working arrangements can reduce stress, and improve productivity and financial resilience, closing the income gaps referred to earlier. They can be even more effective closer to retirement to allow for working in later life and retaining critical experience and skills.

Epigenetics research and the implications of lifestyle-related changes in the cause of disease and aging holds great promise. It could unlock our understanding of how an individual responds to environmental cues and acquired risk factors. It also raises profound ethical questions about the role of the employer and the efficacy of workplace programs and conditions and their unintended consequences.

Read the original here:
Active Aging Could Eliminate the Retirement Funding Gap With the Help of Epigenetics - BRINK

]]]]]] Volitions CEO, Cameron Reynolds spoke to Medical Technology about the companys story so far and what sets their technology apart from others in development. Credit: Volition

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.

Epigenetics company Volition is hoping to carve new ground in the cancer diagnostics space. Through measuring tumour nucleosomes (a type of epigenetic structure) in the blood, it is creating a range of blood tests that can detect cancer from the earliest stages. The company says these tests will be simple, cost-effective and easy to use.

With clinical trials underway, the company is now focused on bringing its toolbox of diagnostic products to market. Volitions CEO, Cameron Reynolds spoke to Medical Technology about the companys story so far and what sets their technology apart from others in development.

Abi Millar (AM): Whats the story behind Volition? Can you tell me a bit about your path to getting where you are today?

Cameron Reynolds (CR): We started ago nearly ten years ago, in September 2010. Were still using the same technology platform as we were then a lot of companies chop and change, but weve always believed in epigenetics and see them as really important in cancer diagnosis.

We started with one original patent application, which was licensed to us from Chroma Therapeutics. We wanted to commercialise this basic concept of using nucleosomes (a type of epigenetic structure) for a marker for cancer detection, and eventually a number of other diseases as well. So we set up a subsidiary in Belgium, which we felt was a good value place to develop research, and raised just over a million euros. We also have offices in Texas, London and Singapore.

Our whole ethos has been to make low-cost, routine cancer diagnostics with an ELISA based format. The ELISA platform is 35 years old our chief scientific officer Jake Micallef has been working on this format his entire life, and hes a big believer in keeping it affordable.

We started with our original patent, which was histone modifications, and then we patented everything else we did along the way, so we have very strong intellectual property. We began with diagnostics for human cancers, starting with colorectal, and then adding in lung cancer and some other cancers where weve had some good results.

Around two and a half years ago, we expanded the staff and moved into a bigger facility in Belgium. We now have 35 people working there, attempting to create a robust, reliable stable platform to measure the tumour nucleosomes in circulation. We went public in 2015 on the New York Stock Exchange, since the capital markets are quite a good source of funding if you have something new and innovative.

Since then weve just been swimming in our own lane, developing our technology. Were in the process of launching a range of products over the next few years, and hopefully we can really do a good job with it.

AM: You are developing a range of blood tests for cancer diagnostics called Nu.Q, which has been described as an epigenetic toolbox. What is Nu.Q exactly? How does it work?

CR: We have several different ways of analysing the nucleosomes, ranging from a very simple microtitre plate-based ELISA format to a magnetic bead-based ELISA format. The new process were developing now, called Nu.Q Capture, involves capturing the nucleosomes on the machine, isolating them from the plasma, and conducting mass spectrometry analysis. This enables a greater concentration of nucleosomes.

Were using Nu.Q for our own purposes in cancer trials and other trials, and have also partnered with Texas A&M Veterinary School to find out whether our basic format could be useful in veterinary science too. Thats why we call Nu.Q a complete toolbox. Its a very robust reliable platform that can be used in all these different areas, and its a whole new way of analysing the epigenetic structures.

AM: What is different about this method, compared to other diagnostic assays for cancer?

CR: Since we started, there have been a lot of different cancer diagnostics in development, based on circulating tumour cells, DNA, exosomes, etcetera. But were still the only group ever to have looked at nucleosomes in circulation as a diagnostic.

We also have the ethos to keep it very affordable and easy to use. With a lot of companies its a complicated, expensive technology circulating DNA for instance requires a very large blood draw and quite expensive processes. Weve kept it simple, and we can do that because the markers were after are common in the blood and you can measure them with a simple ELISA format.

So theres always space for lots of different methods, but we think theres a very strong need for a low cost, reproducible reliable test that can be taken by huge numbers of people around the world as part of their normal medical work. That makes us unique not only in terms of the markers were after the nucleosomes but also in terms of the basic ethos. Weve spent the last two and half years fully optimising the platform itself so it can be robust, reproducible and reliable and accessible to any lab in the world.

AM: You currently have a number of clinical trials underway and presented some initial data at the 2020 ASCO Annual Meeting. What might the path to the clinic look like?

CR: We now have some markers that have shown very good efficacy in a range of cancers, but were also looking for differential markers between the different cancers. Were running some smaller trials for lung, colorectal and blood cancers some of the data was released at ASCO and now were putting together panels of those to get enough accuracy for a frontline test.

We also have some larger trials, like the early detection research network in the US, which will involve around 7,000-8,000 people. There are also some in Taiwan for lung and colorectal cancers, which will involve around 8,000-9,000 altogether.

So, weve got small and medium-sized trials along with some very large product trials. Thats on top of the trials we have in the veterinary space, as well as trials for things like Nu.Q Capture. Weve also had some very encouraging data in Covid-19, where were looking at prognostic outcomes.

Our assays are very low cost and easy to run with small amounts of blood, so we can run them in lots of different areas. There should be a lot of results coming through this year, next year and into 2022.

AM: What are your hopes for the future? What could the implications of your technology be further down the line?

CR: My hope is that our kits will enable much earlier diagnosis. That would really help to lower costs both in human terms and financially. If you get diagnosed early, you can survive it a lot longer of those diagnosed in stage 1, about 95% survive five years or more whereas its exactly the opposite if the cancer is found in stage 4. Thats obviously horrible for yourself and your family but its also a financial burden for health systems.

So hopefully it will have a very strong human impact on limiting the severity of the disease, as well as saving health systems and individuals money. This will make it affordable for healthcare systems in the developed and developing world, so we can hopefully save lives worldwide. And what we hope is that in five years, a large percentage of the worlds population who are either of age or at risk take our blood tests through routine blood work and we can do a lot of good in a lot of different areas.

AM: More generally, what do you expect the future of blood testing for cancer to look like?

CR: I certainly hope the other tests succeed, because particularly in markets like the US where there is an appetite for expensive tests, I think they could be very useful and some of them could be very accurate. So thats always a good thing, but what were providing is a routine, easy to use, lower cost alternative.

I think there are going to be things happening at both ends of the market, both at our end and also at the more complicated end of the market. A lot of it will be based on the epigenetics and not just the DNA the complete package of the epigenetics, the nucleosomes and the whole chromosome will make a big difference.

So, there are quite a few things in development that may work and I think theres going to be a real revolution in cancer diagnostics over the next five years. People will be able to get blood tests to get diagnosed early and hopefully well be a part of that.

Read the rest here:
Q&A: discussing cancer blood testing tech with Volition - Verdict Medical Devices - Medical Device Network